Skip to main content
08-04-2025

New cancer medicines receive reimbursement

Iliustracija

The Compulsory Health Insurance Fund (CHIF) will now reimburse new medicines for various forms of cancer.

“The Ministry of Health, together with the National Health Insurance Fund and the State Medicines Control Authority, is working hard to ensure that new effective cancer medicines reach patients as quickly as possible. Close cooperation between the institutions is helping to speed up the implementation of the legislation and the inclusion of these medicines in the reimbursement system,” said Vice-Minister of Health Daniel Naumovas.

Darolutamide, olaparib, pembrolizumab, abemaciclib and trastuzumab deruxecan are transferred from the reserve list to the reimbursement list. These medicines will help patients with breast, prostate, cervical and oesophageal and gastro-oesophageal junction cancers.

“The list of reimbursable medicines includes essential medicines that were previously on the reserve list awaiting funding. This is good news for thousands of patients - new effective medicines will help them to manage their illness and improve their quality of life,” says Evaldas Stropus, Head of the Pharmaceuticals Reimbursement Division of the National Health Insurance Fund (NHIF).

Sacituzumab govitecan, for more aggressive forms of breast cancer, will shortly be added to the list of reimbursed medicines, while tucatinib, for the treatment of inoperable or advanced breast cancer, will be added to the list of reimbursed medicines following an agreement between the manufacturer and NHIF. In addition, procurement procedures for the purchase of the centrally reimbursed medicine daunorubicin with cytarabine for the treatment of acute myeloid leukaemia will be initiated in the near future.

It is estimated that around EUR 19 million will be added to the CHIF budget this year to reimburse new cancer medicines.

According to the NHIF, the total amount spent on reimbursement of medicines for anti-tumour medicines in 2024 is almost EUR 244 million. This is the amount of public money needed to treat 51.6 thousand patients. It is worth noting that the amount spent on oncology medicines has doubled in the last five years.

Information of the Ministry of Health and NHIF

The NHIF invites you:

Last updated: 16-04-2025

Related news:

Treatment Abroad: When Are Lithuanian Patients Sent to Other Countries and Who Pays?

Migraine: Expert Advice on How to Treat It Rationally and Safely

Improved Access to Treatment: More Medications Reimbursed, Fewer Barriers

Lithuania has already purchased seasonal influenza vaccines

Health insurance funds have completed the signing of contracts: almost 3 billion distributed